SEI Investments’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

SEI Investments’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-420	Closed	-$16K	–	2911
2016 Q4	$16K	Buy	+420	New	+$14.6K	﹤0.01%	2376

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SEI Investments's BCLI Position: Q1 2017 in Review

SEI Investments sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2017, closing a stake of 420 shares — an estimated $16K sold.

SEI Investments first reported a position in BCLI in Q4 2016 and held it in 1 quarter. The position peaked at $16K in Q4 2016. 26 funds tracked by Wall St. Rank hold BCLI as of Q1 2017.

SEI Investments reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2017 after selling out during the quarter.
SEI Investments sold 420 BRAINSTORM CELL THERAPUTC shares in Q1 2017, an estimated $16K.
SEI Investments first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2016 and held it in 1 quarter.
SEI Investments's BRAINSTORM CELL THERAPUTC position peaked at $16K in Q4 2016.
26 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2017.

Based on SEI Investments's 13F filing for Q1 2017, filed 5 May 2017.